Abstract
Pathogenesis research in thyroid cancers aroused interest in the development of new targeted medicinal preparations for these rare tumours. Data from DECISION study underlay the approval of sorafenib as the first tyrosine kinase inhibitor for the treatment of patients with cancers refractory to radioactive iodine, in an indication in which no other standard therapy is available.
Adverse effect profile of sorafenib is known and manageable.